Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
173
resultados
Última actualización
21/11/2025 [07:22:00]
Resultados 25 a 50 de 173
Resumen de: WO2025206567A1
The present invention provides a miRNA biomarker for diagnosing and treating inflammatory bowel disease (IBD). A biomarker according to one embodiment of the present invention can be utilized in a composition for diagnosing inflammatory bowel disease, a method for providing information for diagnosis, a pharmaceutical composition for preventing or treating inflammatory bowel disease, and a method for treating inflammatory bowel disease.
Resumen de: US2025302891A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Resumen de: WO2025199410A1
The disclosed method and system pertain to stratifying a patient population for precision medicine in Inflammatory Bowel Disease (IBD) treatment. The method involves accessing a multi-omic dataset comprising genomic, transcriptomic, and proteomic profiles of patient data. Machine learning algorithms are employed to analyze the dataset and identify biomarkers associated with a response to a drug for treating IBD. The patient population is stratified into phenotypic groups based on the identified biomarkers using unsupervised clustering. A patient population predicted to respond to the drug is defined based on the stratification and further analysis of patient metadata. The system includes a data storage unit and a processor configured to perform the method. The method and system can be used to optimize therapeutic interventions in IBD management.
Resumen de: WO2025193919A1
Methods of identifying a canine subject susceptible to inflammatory bowel disease, methods of treating or preventing inflammatory bowel disease in a canine subject, and compositions useful for treating or preventing inflammatory bowel disease in a canine subject are described herein.
Resumen de: US2025290143A1
Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: KR20250135709A
본 발명은 장 질환 예방 또는 치료용 조성물 및 장 질환 진단을 위한 정보제공방법에 관한 것으로, 인간의 장내 마이크로바이옴 분석을 통해 장 질환과 관련있는 유효 균주를 선별하였으며, 이들 중 크론병 등 장 질환에 치료 효과가 있는 균주를 확인하였는 바, 질병 진단 또는 장 질환의 예방, 개선 및 치료에 유용하게 활용될 수 있다.
Resumen de: WO2025185773A1
Disclosed in the present invention are an antibody targeting TL1A and the use thereof. The antibody of the present invention can be used for blocking the interaction between TL1A and DR3, is helpful for achieving the purpose of intervention from the early stages of inflammation, inhibits immune cells such as effector T cells to release cytokines for promoting an inflammatory response, and provides more possibilities for treatment methods for IBD patients or other TL1A-related diseases.
Resumen de: WO2025186390A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: WO2025185637A1
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Resumen de: WO2025188870A1
Provided herein are methods of identifying a subject as having an inflammatory bowel disorder, wherein a method includes (a) determining a level of NXPE1 in a biological sample from the subject; and (b) comparing the level of NXPE1 in the biological sample to a reference level, wherein the presence of a level of NXPE1 in the biological sample above the reference level indicates that the subject has an inflammatory bowel disorder.
Resumen de: US2025281553A1
Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
Resumen de: EP4614151A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: WO2024094817A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: WO2025181327A1
The present invention relates to a method for determining a need for adjustment of parenteral supplementation, risk of developing acid-base imbalance, and monitoring development of acid-base imbalance in a subject receiving parenteral supplementation and having intestinal insufficiency, such as short bowel. In particular, the present invention relates to determining urinary net acid excretion (NAE) for evaluating acid-base imbalances in subjects having intestinal insufficiency, such as short bowel, in order to determine risk of developing and/or monitoring development of acid-base imbalance, as well as adjustment of parenteral supplementation.
Resumen de: WO2025181330A1
The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).
Resumen de: WO2025184435A1
The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.
Resumen de: US2025277269A1
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: EP4610657A1
Provided are a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
Resumen de: US2025243548A1
Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.
Resumen de: MX2025009868A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.
Resumen de: CN120577530A
The invention discloses a therapeutic target for inflammatory bowel disease and application thereof. Research finds that NO can be combined with an enzyme active site of a CYP450 family member, so that the activity of the CYP450 family member is inhibited, finally generation of a pathogenic factor GM-CSF is inhibited, and enteritis is relieved. On the basis, an inflammatory bowel disease product, a kit and an analysis system are developed. According to the invention, a new strategy can be provided for preventing, detecting and treating intestinal inflammatory diseases, and the intestinal homeostasis imbalance can be effectively improved.
Resumen de: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Nº publicación: CN120554525A 29/08/2025
Solicitante:
UNIV CHINESE HONG KONG SHENZHEN
HONG KONG CHINESE UNIV SHENZHEN FUTIAN BIOLOGICAL MEDICINE INNOVATION RESEARCH AND DEVELOPMENT CENTE
\u9999\u6E2F\u4E2D\u6587\u5927\u5B66\uFF08\u6DF1\u5733\uFF09,
\u9999\u6E2F\u4E2D\u6587\u5927\u5B66\uFF08\u6DF1\u5733\uFF09\u798F\u7530\u751F\u7269\u533B\u836F\u521B\u65B0\u7814\u53D1\u4E2D\u5FC3
Resumen de: CN120554525A
The invention provides a fusion protein as well as a preparation method and application thereof. Specifically, the fusion protein disclosed by the invention has a structure as shown in a formula I: in the formula, Z0 is a tag sequence for purposes of purification, separation and the like; z1 is a human serum amyloid A protein fragment; l1 is none or a joint; z2 is fluorescent protein. The invention provides a preparation method and application of the fusion protein, the method is high in yield and free of risks of cross infection, gene mutation and the like, and the Clover-SSA1 protein prepared through the method can be used in the research fields of disease diagnosis, drug screening, biomarkers and the like, namely Z0-Z1-L1-Z2 (I).
BOPI
Sede Electrónica
